Efficacy of Ocrelizumab on Brain MRI Outcomes in Patients with Early Relapsing Multiple Sclerosis: Pooled Analysis of the OPERA Studies (P6.338)

Conclusions:Ocrelizumab reduced brain MRI lesion activity and the rate of brain volume loss vs IFNβ-1a in patients with early RMS.Study Supported by:Sponsored by F. Hoffmann-La Roche Ltd.Disclosure: Dr. Traboulsee has received personal compensation for activities with Genzyme and Roche as a consultant. Dr. Traboulsee has received research support from Genzyme, Roche, and Chugai. Dr. Hauser has received personal compensation for activities with Annexon, Symbiotix, Bionure as a scientific advisory board member and from F. Hoffmann-La Roche Ltd. Dr. Havrdova has received personal compensation for activities with Biogen, Merck Serono, Novartis, Sanofi-Genzyme, and Teva as an speaker. Dr. Havrdova has received research support from Biogen. Dr. Kappos has reveived personal compensation for activities with University Hospital Basel as an advisory board member. Dr. Kappos has received research support from Swiss Multiple Sclerosis Society, Swiss National Research Foundation, European Union, Gianni Rubatto Foundation, Novartis Research Foundation, and Roche Research Foundation. Dr. Racke has received personal compensation for activities with Abbvie, Novartis, Roche, Genentech, TG Therapeutics, and Teva Neuroscience as a consultant. Dr. Racke has received personal compensation in an editorial capacity for JAMA Neurology and The Journal of Neuroimmunology. Dr. Racke has received research support from Diogenix, Roche/Genentech, Novartis, Actelion, TG Therapeutics, and Alkermes. Dr. ...
Source: Neurology - Category: Neurology Authors: Tags: Disease Modifying Therapy for Multiple Sclerosis: Efficacy and Clinical Trial Outcomes I Source Type: research